Recently Diagnosed or Relapsed? Stop Looking For a Miracle Cure, and Use Evidence-Based Therapies To Enhance Your Treatment and Prolong Your Remission

Multiple Myeloma an incurable disease, but I have spent the last 25 years in remission using a blend of conventional oncology and evidence-based nutrition, supplementation, and lifestyle therapies from peer-reviewed studies that your oncologist probably hasn't told you about.

Click the orange button to the right to learn more about what you can start doing today.

Multiple Myeloma Chemos That Cause Kidney Damage

Share Button

“In this review, we recognized that there are multiple ways novel anti- multiple myeloma therapies can affect renal function, cause kidney damage”

Kidney damage is tricky for the multiple myeloma (MM) patient and survivor because MM itself can damage your kidneys. Kidney damage can be a symptom of MM. Further, as the article linked below explains, MM chemotherapy itself causes kidney damage as well.

In all, according to the second article excerpted below, approximately 13% of MM patients die of renal damage aka kidney failure.

The scariest problem facing newly diagnosed MM patients is quoted in the top article in the very first sentence “effects of these therapies can lead to unanticipated effects on the kidney.” In other words, some of these “novel” MM therapies are not old enough, have not been tested enough for oncology to thoroughly understand the degree of kidney damage caused by novel chemotherapy regimens.

Lastly, and this is my own perspective on MM chemotherapy drugs, the negative kidney effects cannot be fully know and understood, until years after chemo administration. Like all long-term and late stage side effects, a MM patient can’t know the full extent of his or her kidney damage until they’ve lived beyond their MM diagnosis for years, even decades, beyond their original MM diagnosis.

Just knowing they kidney damage can be an issue for multiple myeloma patients can help. Also, there are a number of foods and supplements that can help your kidneys heal.

Also, don’t forget that the bone strenthener denosumab is much easier on your kidneys that bisphophonate therapies are.

Have you been diagnosed with multiple myeloma? Scroll down the page, post a question or comment and I will reply to you ASAP.

Thank you,

David Emerson

  • MM Survivor
  • MM Cancer Coach
  • Director PeopleBeatingCancer

Recommended Reading:

Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma

“In some cases, off target effects of these therapies can lead to unanticipated effects on the kidney that can range from electrolyte disorders to AKI…

In addition, some novel MM therapies have also been reported to cause kidney injury. These adverse effects are likely to have negative effects on prognosis and may limit the ability of the patient to receive effective treatment. Given myeloma itself can lead to kidney disease, distinguishing between myeloma-related kidney disease and drug toxicity is difficult without a kidney biopsy…

In summary, both lenalidomide and pomalidomide have been associated with kidney dysfunction; however, clinicians must be careful when assessing patients with worsening kidney disease on IMiD as a number of other causes including progression of MM could be responsible for decline in kidney function…


The use of novel targeted therapies has led to significant improvements in survival and overall prognosis with many malignancies. However, there is evolving knowledge of renal adverse events with these agents. Timely recognition of these toxicities can aid in the proper management of patients with myeloma.

In this review, we recognized that there are multiple ways novel antimyeloma therapies can affect renal function. In addition, newer targeted agents are entering clinical trials. With the advent of novel targeted therapies and their use in myeloma, nephrologists and hematologists need to be more vigilant of the renal toxicity potential of these agents…”

A systematic classification of death causes in multiple myeloma

“The most common MM progression-related (1A) SOCs (n = 163) were neoplasms (50.9%, n = 83), infections (15.3%, n = 25), renal disorders (12.9%, n = 21), and cardiac disorders (6.7%, n = 11, Fig. 2c). Expressed in the high specific MedDRA term PT, MM (48.5%, n = 79), renal failure (12.9%, n = 21), sepsis (4.3%, n = 7) and pneumonia as well as cardiopulmonal failure (3.7%, n = 6 each) were leading (Fig. 2e)…”



Leave a Comment: